FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

Oncologist

Volumn 19, Issue 8, 2014, Pages 845-850

  Pietrantonio, Filippo ^a   Maggi, Claudia ^a   Fanetti, Giuseppe ^a   Iacovelli, Roberto ^a   Di Bartolomeo, Maria ^a   Ricchini, Francesca ^a   Deraco, Marcello ^a   Perrone, Federica ^a   Baratti, Dario ^a   Kusamura, Shigeki ^a   Tamborini, Elena ^a   Castano, Alessandra ^a   Consonni, Paola Valentina ^a   Bossi, Ilaria ^a   Gavazzi, Cecilia ^a   Milione, Massimo ^a   Pelosi, Giuseppe ^a   de Braud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Appendiceal cancer; Chemotherapy; FOLFOX 4; Peritoneal pseudomyxoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; KRAS PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; ONCOPROTEIN; PLATINUM COMPLEX; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OBSERVATIONAL STUDY; ONCOGENE N RAS; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; DISEASE FREE SURVIVAL; DNA METHYLATION; FOLLOW UP; GENETICS; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS; PSEUDOMYXOMA PERITONEI; RAS PROTEINS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84905466126     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0106     Document Type: Article

References (34)

1. Smeenk RM, van Velthuysen ML, Verwaal VJ et al. Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. Eur J SurgOncol 2008; 34: 196-201.
2. Bosman FT, Carneiro F, Hruban RH, eds. et al. WHO Classification of Tumours of the Digestive System. 4th edLyon, France: International Agency for Research on Cancer, 2010.
3. Bradley RF, Stewart JH IV, Russell GB et al. Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006; 30: 551-559.
4. Austin F, Mavanur A, Sathaiah M et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol 2012; 19: 1386-1393.
5. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7: 69-76.
6. Chua TC, Moran BJ, Sugarbaker PH et al. Earlyand long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449-2456.
7. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: Biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 2009; 249: 243-249.
8. August DA, Huhmann MB. A. S. P. E. N. clinical guidelines: Nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009; 33: 472-500.
9. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
10. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
11. Di Bartolomeo M, Pietrantonio F, Perrone F et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2014; 9: 155-162.
12. Molinari F, Felicioni L, Buscarino M et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-4914.
13. Herman JG, Graff JR, Myöhänen S et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
14. Pietrantonio F, Perrone F, de Braud F et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol 2014; 25: 404-408.
15. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 1996; 82: 235-253.
16. Smeenk RM, Verwaal VJ, Antonini N et al. Progression of pseudomyxoma peritonei after combined modality treatment: Management and outcome. Ann Surg Oncol 2007; 14: 493-499.
17. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol 2007; 14: 2289-2299.
18. Baratti D, Kusamura S, Martinetti A et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2007; 14: 2300-2308.
19. Smith JW, Kemeny N, Caldwell C et al. Pseudomyxoma peritonei of appendiceal origin. The MemorialSloan-KetteringCancer Center experience. Cancer 1992; 70: 396-401.
20. Gough DB, Donohue JH, Schutt AJ et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219: 112-119.
21. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: Clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008; 15: 526-534.
22. Skipper HE, Schabel FM Jr., Mellett LB et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970; 54: 431-450.
23. Shapiro JF, Chase JL, Wolff RA et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: A single-institution experience. Cancer 2010; 116: 316-322.
24. Farquharson AL, Pranesh N, Witham G et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008; 99: 591-596.
25. Sugarbaker PH, Bijelic L, Chang D et al. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010; 102: 576-581.
26. Sun WL, Hutarew G, Gradl J et al. Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther 2009; 8: 1459-1462.
27. Powell ED, Macdonald DB, Elkeilani AM et al. A case of appendiceal adenocarcinoma with clinical benefit from FOLFOX and bevacizumab. Case Rep Oncol 2009; 2: 111-115.
28. Von Hoff DD, Stephenson JJ Jr., Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
29. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
30. Ichikawa Y, Nishida M, Suzuki H et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994; 54: 33-35.
31. Raghav KP, Shetty AV, Kazmi SM et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. The Oncologist 2013; 18: 1270-1277.
32. Kabbani W, Houlihan PS, Luthra R et al. Mucinous and nonmucinous appendiceal adenocarcinomas: Different clinicopathological features but similar genetic alterations. Mod Pathol 2002; 15: 599-605.
33. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
34. Fine RE, Gulati AP, Tsushima Det al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and welldifferentiated metastatic neuroendocrine tumors. J Clin Oncol 2014; 32(suppl 3): 179a.